Holen Sie sich die Stockscreener-App
1.47
2.41%
0.01
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ONCT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.46
Offen:
$1.4
24-Stunden-Volumen:
116.35K
Relative Volume:
4.44
Marktkapitalisierung:
$4.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.48M
KGV:
-1.9342
EPS:
-0.76
Netto-Cashflow:
$-32.16M
1W Leistung:
-63.26%
1M Leistung:
-59.70%
6M Leistung:
-81.36%
1J Leistung:
-78.64%
1-Tages-Spanne:
$1.40
$1.55
1-Wochen-Bereich:
$1.32
$4.4334
52-Wochen-Spanne:
$1.32
$13.14
Oncternal Therapeutics Inc Stock (ONCT) Company Profile
Firmenname
Oncternal Therapeutics Inc
Sektor
Branche
Telefon
(858) 434-1113
Adresse
12230 EL CAMINO REAL, SAN DIEGO, CA
Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-23 | Eingeleitet | Northland Capital | Outperform |
Oncternal Therapeutics Inc Aktie (ONCT) Neueste Nachrichten
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com - Defense World
Oncternal Therapeutics Axes B-Cell Lymphoma Trial for CAR-T Therapy ONCT-808 - CGTLive™
Oncternal Therapeutics (NASDAQ:ONCT) Downgraded by Northland Capmk - Defense World
Oncternal stock crashes by 60% as it lays off staff and scraps trials - Pharmaceutical Technology
Oncternal stock crashes by 60% as it lays off staff and scraps trials - Clinical Trials Arena
Oncternal stock crashes by 60% as it lays off staff and scraps trials - Yahoo Finance
Analyzing the Impact of Earnings Reports on Oncternal Therapeutics Inc Inc. (ONCT) Price Performance - The InvestChronicle
Director Wills Robert James acquire 3,086 shares of Oncternal Therapeutics Inc [ONCT] - Knox Daily
In the Green: Oncternal Therapeutics Inc (ONCT) Closes at 1.70, Up/Down -59.09 from Previous Day - The Dwinnex
Oncternal plunges on portfolio shakeup - MSN
Denali Therapeutics Inc [DNLI] stock for 77,007 USD was sold by SATO VICKI L - Knox Daily
Oncternal Therapeutics announces workforce reduction and trial discontinuations - Investing.com
Oncternal Therapeutics Cuts Jobs, Discontinues Product Development Amid Business Review - MarketWatch
Oncternal Therapeutics Restructures Amid Clinical Setbacks - TipRanks
Oncternal stock plunges on portfolio shakeup (NASDAQ:ONCT) - Seeking Alpha
Oncternal halts trials for cancer treatments, seeks alternatives - Investing.com
Oncternal Therapeutics Ends Development Activities, Mulls Options - MarketWatch
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives - GlobeNewswire
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives - Yahoo Finance
Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com - Defense World
Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.com - Defense World
ONCT (Oncternal Therapeutics) Financial Strength : 8 (As of Jun. 2024) - GuruFocus.com
Oncternal Therapeutics (NASDAQ:ONCT) PT Lowered to $18.00 at HC Wainwright - Defense World
Oncternal Therapeutics Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript - Seeking Alpha
Oncternal Therapeutics: Q2 Earnings Snapshot - CTPost
Oncternal Therapeutics: Q2 Earnings Snapshot - Houston Chronicle
Oncternal Therapeutics: Q2 Earnings Snapshot - New Haven Register
Oncternal Therapeutics: Q2 Earnings Snapshot - CT Insider
ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates - MSN
Oncternal Therapeutics: Q2 Earnings Snapshot - San Francisco Chronicle
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - BioSpace
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Oncternal Therapeutics: Q2 Earnings Snapshot - Danbury News Times
Oncternal Therapeutics: Q2 Earnings Snapshot - The Bakersfield Californian
Oncternal Therapeutics (NASDAQ:ONCT) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - GlobeNewswire
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - StockTitan
Oncternal Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Oncternal Therapeutics (ONCT) Scheduled to Post Quarterly Earnings on Thursday - Defense World
ROR1 in Focus as a target for ADC-based treatments: Recent Developments and Industry ChallengesPart III - geneonline
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by StockNews.com - Defense World
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results - GlobeNewswire
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results - StockTitan
HC Wainwright Reiterates Buy Rating for Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
When the Price of (ONCT) Talks, People Listen - Stock Traders Daily
Oncternal Announces Enrollment Completed and Dosing - GlobeNewswire
Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - StockTitan
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - American Banking and Market News
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit - StockTitan
Finanzdaten der Oncternal Therapeutics Inc-Aktie (ONCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oncternal Therapeutics Inc-Aktie (ONCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wills Robert James | Director |
Mar 28 '24 |
Buy |
8.48 |
6,914 |
58,602 |
6,914 |
| HALE DAVID F | Director |
Feb 23 '24 |
Buy |
9.04 |
714 |
6,455 |
714 |
| HALE DAVID F | Director |
Feb 23 '24 |
Buy |
9.04 |
266 |
2,405 |
29,673 |
| Wills Robert James | Director |
Feb 23 '24 |
Sale |
9.04 |
980 |
8,859 |
0 |
1.19%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):